XT
BRNS

XTX Topco’s Barinthus Biotherapeutics BRNS Stock Holding History

XTX Topco’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,007
Closed -$16.3K – 3344
2025
Q3 		$16.3K Buy
+13,007
New +$16.3K ﹤0.01% 2365

Other funds holding BRNS

HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

XTX Topco's BRNS Position: Q4 2025 in Review

XTX Topco sold out of Barinthus Biotherapeutics (BRNS) in Q4 2025, closing a stake of 13,007 shares — an estimated $16.3K sold.

XTX Topco first reported a position in BRNS in Q3 2025 and held it in 1 quarter. The position peaked at $16.3K in Q3 2025. 13 funds tracked by Wall St. Rank hold BRNS as of Q4 2025.

  • XTX Topco reported no remaining Barinthus Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • XTX Topco sold 13,007 Barinthus Biotherapeutics shares in Q4 2025, an estimated $16.3K.
  • XTX Topco first reported a position in Barinthus Biotherapeutics in Q3 2025 and held it in 1 quarter.
  • XTX Topco's Barinthus Biotherapeutics position peaked at $16.3K in Q3 2025.
  • 13 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.